284 related articles for article (PubMed ID: 15667909)
21. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone.
Dupont HL; Jiang ZD; Belkind-Gerson J; Okhuysen PC; Ericsson CD; Ke S; Huang DB; Dupont MW; Adachi JA; De La Cabada FJ; Taylor DN; Jaini S; Martinez Sandoval F
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):451-6. PubMed ID: 17382603
[TBL] [Abstract][Full Text] [Related]
22. Rifaximin--the promising anti-microbial for enteric infections.
Arya SC; Agarwal N
J Infect; 2005 Oct; 51(3):262. PubMed ID: 16125780
[No Abstract] [Full Text] [Related]
23. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.
Gillis JC; Brogden RN
Drugs; 1995 Mar; 49(3):467-84. PubMed ID: 7774516
[TBL] [Abstract][Full Text] [Related]
24. Rifaximin: a new treatment for travelers' diarrhea.
Pakyz AL
Ann Pharmacother; 2005 Feb; 39(2):284-9. PubMed ID: 15598963
[TBL] [Abstract][Full Text] [Related]
25. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic.
Scarpignato C; Pelosini I
Digestion; 2006; 73 Suppl 1():13-27. PubMed ID: 16498249
[TBL] [Abstract][Full Text] [Related]
26. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
Putnam SD; Castanheira M; Moet GJ; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):393-401. PubMed ID: 20022192
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
Bruzzese E; Pesce M; Sarnelli G; Guarino A
Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
[TBL] [Abstract][Full Text] [Related]
28. Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.
DuPont HL; Petersen A; Zhao J; Mundt A; Jiang ZD; Miller S; Flores J; Shringarpure R; Moro L; Bagin RG; Ballard ED; Totoritis MC
J Travel Med; 2014; 21(6):369-76. PubMed ID: 25345982
[TBL] [Abstract][Full Text] [Related]
29. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
30. Rifaximin (Xifaxan) for travelers' diarrhea.
Med Lett Drugs Ther; 2004 Sep; 46(1191):74-5. PubMed ID: 15365508
[No Abstract] [Full Text] [Related]
31. Biologic properties and clinical uses of rifaximin.
DuPont HL
Expert Opin Pharmacother; 2011 Feb; 12(2):293-302. PubMed ID: 21226639
[TBL] [Abstract][Full Text] [Related]
32. Rifaximin: in vitro and in vivo antibacterial activity--a review.
Jiang ZD; DuPont HL
Chemotherapy; 2005; 51 Suppl 1():67-72. PubMed ID: 15855749
[TBL] [Abstract][Full Text] [Related]
33. Rifaximin in the treatment of infectious diarrhea.
Ericsson CD; DuPont HL
Chemotherapy; 2005; 51 Suppl 1():73-80. PubMed ID: 15855750
[TBL] [Abstract][Full Text] [Related]
34. Rifaximin: beyond the traditional antibiotic activity.
Calanni F; Renzulli C; Barbanti M; Viscomi GC
J Antibiot (Tokyo); 2014 Sep; 67(9):667-70. PubMed ID: 25095806
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity and fecal concentration of rifaximin after oral administration.
Jiang ZD; Ke S; Palazzini E; Riopel L; Dupont H
Antimicrob Agents Chemother; 2000 Aug; 44(8):2205-6. PubMed ID: 10898704
[TBL] [Abstract][Full Text] [Related]
36. Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment.
Okhuysen PC
Curr Opin Infect Dis; 2005 Dec; 18(6):522-6. PubMed ID: 16258326
[TBL] [Abstract][Full Text] [Related]
37. Rifamycin (Aemcolo) for treatment of travelers' diarrhea.
Med Lett Drugs Ther; 2019 Mar; 61(1567):39-40. PubMed ID: 30845098
[No Abstract] [Full Text] [Related]
38. Rifaximin: a review of its use in the management of traveller's diarrhoea.
Robins GW; Wellington K
Drugs; 2005; 65(12):1697-713. PubMed ID: 16060706
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.
Hoover WW; Gerlach EH; Hoban DJ; Eliopoulos GM; Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 1993 Feb; 16(2):111-8. PubMed ID: 8385592
[TBL] [Abstract][Full Text] [Related]
40. Eradication of Helicobacter pylori: are rifaximin-based regimens effective?
Gasbarrini A; Gasbarrini G; Pelosini I; Scarpignato C
Digestion; 2006; 73 Suppl 1():129-35. PubMed ID: 16498261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
